Exelixis Inc vs Eli Lilly & Co.
EXEL vs LLY — side-by-side comparison from reported financials. EXEL leads 3, LLY leads 6 of 9 comparable metrics.
Exelixis Inc
EXEL · Healthcare
$60.62+2.71%Mixed
Eli Lilly & Co.
LLY · Healthcare
$1 177.20+0.65%Solid
| Metric | EXEL | LLY |
|---|---|---|
| Price | $60.62 | $1 177.20 |
| Market cap | $15.0B | $1.05T |
| Revenue (TTM) | $2.44B | $79.7B |
| Revenue growth | +12.9% | +31.7% |
| Net margin | 35.3% | 33.5% |
| Free cash flow | $1.17B | $18.2B |
| Net cash (debt) | — | ($35.2B) |
| 1-year price return | +57.2% | +37.6% |
| P/E | 17.2 | 41.6 |
| P/E vs own history (cheap-side %) | 81% | 88% |
| Dividend yield | — | 0.52% |
| Return on equity | 42% | 93% |
| Altman Z-score | — | 7.10 |
| CV checks passed | 9 of 10 | 11 of 10 |
| Employees | 1,077 | 50,000 |
Full résumé-style profiles: EXEL CV · LLY CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.